1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA <LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY)
2011; Elsevier BV; Volume: 54; Linguagem: Inglês
10.1016/s0168-8278(11)61372-x
ISSN1600-0641
AutoresE. Läwitz, M. Rodríguez‐Torres, Jill Denning, M. Cornpropsr, D. Clemons, Laura F. McNair, M. Michelle Berrey, William T. Symonds,
Tópico(s)Medical Imaging Techniques and Applications
Resumoand 48% of CC, CT and TT telaprevir patients respectively, had undetectable HCV RNA at weeks 4 and 12 (eRVR) compared with 16%, 3% and 0% of PR patients.Among eRVR telaprevir patients, 91% achieved SVR (97% of CC, 88% of CT/TT) with 24 weeks of therapy whereas 45% of non-eRVR telaprevir patients had SVR (67% of CC, 38% CT/TT) with 48 weeks of therapy.Conclusions: Telaprevir-based therapy improved eRVR and SVR rates across all IL28B genotypes.Specifically, telaprevir-based therapy more than doubled the rates of SVR in CT/TT patients, and substantially increased SVR rates in those with CC genotype, as compared with PR therapy alone.Non-attainment of eRVR was associated with lower SVR rates across all IL28B genotypes, with the largest decrement in CT/TT patients.
Referência(s)